Clinical trial
Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
NCT02954796 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- December 31, 2016
- Completion date
- July 17, 2019
- Enrollment
- 27 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.